Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
F

Current Immunotherapy and Targeted Therapy Standard of Care in Biliary Tract Cancer: Dabrafenib-Trametinib for BRAF+, Infigratinib for FGFR+, Ivsidenib for IDH-1, and Pembro for MSI-H Tumors

By Xth Eurasian Hematology-Oncology Congress FEATURING Fatih Kose
By Xth Eurasian Hematology-Oncology Congress FEATURING Fatih Kose
68 views
December 4, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
Gastrointestinal
17:19
Xth Eurasian Hematology-Oncology Congress

New (Neo)Adjuvant Standards of Care in Gastro-Esophageal Cancer: FLO…

Feat. M. Artac
06:28
Xth Eurasian Hematology-Oncology Congress

Current Chemo Standard of Care in Biliary Tract Cancer: Cisplatin+Ge…

Feat. F. Kose
11:12
Xth Eurasian Hematology-Oncology Congress

Current Immunotherapy and Targeted Therapy Standard of Care in Bilia…

Feat. F. Kose
17:21
Xth Eurasian Hematology-Oncology Congress

Has Sorafenib Still Been the Real Winner Against New Generation TKIs…

Feat. S. Lacin
21:17
Xth Eurasian Hematology-Oncology Congress

Systemic Therapy Options for Metastatic Well-Differentiated Gastroin…

Feat. A. Kouzminov
18:59
Xth Eurasian Hematology-Oncology Congress

Is Tumor Sidedness, Biomarkers or Molecular Subtype Classification M…

Feat. G. Demir